The Effect of Beetroot Extract supplementation on metabolic, hepatic, andinflammation parameters in patients with metabolic-dysfunction associatedSteatotic liver disease.

The Effect of Beetroot Extract supplementation on metabolic, hepatic, and inflammation parameters in patients with metabolic-dysfunction associated Steatotic liver disease.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100524004010N42

Enrollment

Registered

2025-10-20

Start date

2025-10-23

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: ntervention group: Participants in this group received beetroot extract supplementation (1 g per day equivalent to two 500mgr tablets) in combination with a calorie-restricted weight l

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 65 years old Diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) confirmed by a gastroenterology subspecialist Liver steatosis score >263 on FibroScan Body mass index (BMI) >25

Exclusion criteria

Exclusion criteria: Lack of willingness to continue participation or non-adherence to the intervention Pregnancy or lactation Alcohol consumption Presence of other liver diseases Presence of cirrhosis or hepatocellular carcinoma Use of corticosteroid medications such as prednisolone, hydrocortisone, or betamethasone Use of hepatotoxic drugs such as tamoxifen, phenytoin, amoxifen, or lithium Use of liver-affecting supplements (e.g., fiber, omega-3, antioxidants) during the past 6 months Changes in medications (lipid-lowering agents, antidiabetic drugs) during study participation Use of weight-loss drugs or supplements Following any type of weight-loss diet within the past 3 months Weight reduction greater than 10% in the last 6 months (prior to enrollment)

Design outcomes

Primary

Measure	Time frame
Hepatic steatosis. Timepoint: Before intervention and after 12 weeks. Method of measurement: Fibroscan.	—

Secondary

Measure	Time frame
Blood glucose profile. Timepoint: At the beginning and end of the study (week 12). Method of measurement: Blood test.;Blood lipid profile. Timepoint: At the beginning and end of the study (week 12). Method of measurement: Blood test.;Liver enzymes. Timepoint: At the beginning and end of the study (week 12). Method of measurement: Blood test.;C-reactive Protein. Timepoint: At the beginning and end of the study (week 12). Method of measurement: Blood test.	—

Measure

Time frame

Blood glucose profile. Timepoint: At the beginning and end of the study (week 12). Method of measurement: Blood test.;Blood lipid profile. Timepoint: At the beginning and end of the study (week 12). Method of measurement: Blood test.;Liver enzymes. Timepoint: At the beginning and end of the study (week 12). Method of measurement: Blood test.;C-reactive Protein. Timepoint: At the beginning and end of the study (week 12). Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzita Hekmatdoost

Shahid Beheshti University of Medical Sciences

a_hekmat2000@yahoo.com+98 21 2235 7486

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026